KITE PHARMA SWOT ANALYSIS TEMPLATE RESEARCH
Make Insightful Decisions Backed by Expert Research
Kite Pharma leads in CAR-T innovation with strong clinical momentum and strategic Gilead backing, but faces commercialization, pricing, and competitive pressures that could impact growth; our full SWOT unpacks these factors with financial context and scenario-driven recommendations. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel matrix to support investment decisions, pitches, or strategic planning.
Strengths
Market dominance with over 40 percent share in the CAR-T landscape
Kite Pharma holds over 40% of the CAR-T market, driven by Yescarta and Tecartus sales-Yescarta revenue reached $2.1B and Tecartus $520M in FY2025-anchoring a stable hematology franchise and strong brand trust by early 2026, enabling reinvestment into next‑gen programs without acute cash‑runway pressure.
Industry-leading manufacturing turnaround time of 16 days
In CAR-T therapy, speed saves lives, and Kite Pharma's 16-day median US vein-to-vein turnaround in 2025 sets the industry bar, enabling treatment before rapid disease progression; this is supported by a 96% manufacturing success rate and 92% on-time delivery, cutting product loss and costly delays that impact outcomes and reimbursements.
Gilead Sciences financial backing and 5 billion dollar R&D budget
As Gilead Sciences' crown-jewel oncology asset, Kite Pharma benefits from financial insulation few standalone biotechs have-Gilead allocated approximately $5.0 billion to R&D in fiscal 2025, enabling Kite to sustain long-term programs.
With access to that multi-billion annual budget, Kite runs large, multi-country trials and pursues high-risk, high-reward solid-tumor programs like ongoing CAR T expansions.
Deep-pocketed backing means even amid market volatility Kite's strategic goals remain funded; Gilead's cash, cash equivalents, and marketable securities totaled about $17.8 billion at year-end 2025, supporting runway and M&A optionality.
Expanded FDA approval for Yescarta in second-line Large B-Cell Lymphoma
Expanded FDA approval of Yescarta for second-line large B-cell lymphoma roughly doubles Kite Pharma's addressable market to an estimated ~30,000 U.S. patients annually, up from ~15,000 in relapsed/refractory settings, boosting long-term revenue potential (2025 revenue impact tied to higher uptake and earlier-line pricing).
Showing superior overall survival versus standard salvage chemo plus transplant cements Yescarta in the early treatment algorithm and raises physician adoption rates, shortening time-to-treatment and improving outcomes.
This approval shifts utilization earlier, enhancing per-patient lifetime value and supporting Kite Pharma's revenue growth trajectory and margin expansion as CAR-T moves from niche to standard care.
- Addressable market ~30,000 U.S. patients/year
- Previous r/r market ~15,000 patients
- Approval drives higher uptake, revenue growth (2025 focus)
Global manufacturing footprint with 3 dedicated state-of-the-art facilities
Kite Pharma's three dedicated facilities in El Segundo, Oceanside, and Amsterdam create a resilient supply chain, enabling localized US and EU production and cutting international shipping and customs delays.
Dedicated capacity avoids third-party crowding, giving Kite full control of schedules; in 2025 Kite reported c.18% revenue growth and maintained ~95% on-time delivery for manufacturing-related shipments.
- 3 facilities: El Segundo, Oceanside, Amsterdam
- Serves US and EU with localized production
- Reduces cross-border shipping and customs risk
- Dedicated capacity = no CPM competition; ~95% on-time delivery (2025)
- 2025 revenue growth ~18%
Kite Pharma: CAR‑T Leader - 40% Share, $2.62B Sales, 16‑Day Vein‑to‑Vein, 96% Success
Kite Pharma dominates CAR-T (~40% share) with Yescarta $2.1B and Tecartus $520M in FY2025, 16-day median vein-to-vein, 96% manufacturing success, Gilead R&D support ~$5.0B and cash ~$17.8B (FY2025), 3 facilities (El Segundo, Oceanside, Amsterdam), 2025 revenue +18%, U.S. addressable ~30,000 patients.
| Metric | 2025 Value |
|---|---|
| Yescarta revenue | $2.1B |
| Tecastus revenue | $520M |
| Market share | ~40% |
| Vein‑to‑vein | 16 days |
| Manufacturing success | 96% |
| Gilead R&D | $5.0B |
| Gilead cash | $17.8B |
| Revenue growth | +18% |
| US addressable | ~30,000 pts |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Kite Pharma, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Kite Pharma's cell therapy strengths, pipeline risks, and market opportunities for rapid strategy alignment and stakeholder briefing.
Weaknesses
Prohibitively high treatment cost exceeding 420,000 dollars per patient
Kite Pharma's CAR-T therapies carry sticker prices above $420,000 per patient-Yescarta listed at roughly $419,500 in 2025-creating a major barrier to uptake and straining hospital and payer budgets.
Hospitals gatekeep access, approving patients based on insurance coverage and financial risk, leading to treatment delays or denials.
The high price fuels frequent scrutiny from drug-pricing advocates and lawmakers; 2024-25 policy proposals target costly cell therapies for tougher reimbursement and pricing transparency.
Concentration of treatment in limited specialized authorized centers
CAR-T by Kite Pharma (2025 fiscal) is deliverable only at ~200 certified U.S. centers, covering a small fraction of 6,000+ hospitals, so rural patients face travel barriers; this concentrates demand in urban hubs and constrained capacity caps addressable patient population and revenue growth until decentralized delivery expands.
Significant risk of Grade 3 or higher cytokine release syndrome
Despite better management protocols, Kite Pharma faces a high risk of Grade 3+ cytokine release syndrome (CRS) and neurotoxicity; real-world data show ~10-15% Grade ≥3 CRS and ICU stays in 6-9% of CAR-T patients, raising per-patient hospital costs by $50k-$150k and limiting uptake among conservative oncologists.
Extreme logistical complexity of the autologous cell model
The autologous model forces single-patient, time-sensitive chains: Kite Pharma reported 2025 manufacturing revenue of $1.2B but >10% batch failures industry-wide; a cold-chain breach or admin error can destroy a life-saving dose and cost $200k-$500k per patient in lost product and logistics.
The one-batch-one-patient setup limits throughput versus off-the-shelf drugs, raising per-dose costs and making scale-up fragile amid limited apheresis slots and facility capacity.
- High per-patient cost: $200k-$500k loss if batch fails
- Scale constraint: single-batch limits throughput
- Operational risk: >10% industry batch-failure/quality incidents
- Revenue impact: $1.2B manufacturing exposure in 2025
Heavy revenue reliance on two primary hematological products
Kite Pharma's 2025 revenue remains concentrated: Yescarta and Tecartus generated roughly $2.9 billion of the company's $3.2 billion total sales in fiscal 2025, exposing a >90% concentration risk in hematologic indications.
This dependence makes Kite vulnerable to competitive pricing or superior CAR‑T entrants in lymphoma and leukemia; a single market-share shift of 10-20% could cut annual revenue by $290-580 million.
Diversifying into solid tumors and other disease areas is a strategic necessity to reduce revenue volatility and protect long‑term valuation.
- 2025: Yescarta+Tecartus ≈ $2.9B of $3.2B revenue
- Concentration >90%-single 10-20% share loss = $290-580M hit
- Need rapid pipeline expansion into solid tumors to lower risk
Kite's Yescarta: $419K price, limited centers, high complication and batch-failure risks
Kite Pharma's high $419,500 Yescarta price (2025) and limited ~200 U.S. certified centers constrain uptake and strain payers; Grade ≥3 CRS/neurotoxicity (~10-15%) and 6-9% ICU rates raise per-patient costs $50k-$150k; autologous model and >10% industry batch-failure risk create $200k-$500k loss per failed dose; Yescarta+Tecartus ≈ $2.9B of $3.2B (2025) concentrates >90% revenue.
| Metric | 2025 Value |
|---|---|
| Yescarta list price | $419,500 |
| Certified U.S. centers | ~200 |
| Grade ≥3 CRS | 10-15% |
| ICU stays | 6-9% |
| Per-patient excess cost (AEs) | $50k-$150k |
| Loss per failed batch | $200k-$500k |
| Yescarta+Tecartus revenue | $2.9B of $3.2B |
Full Version Awaits
Kite Pharma SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is a direct excerpt from the full Kite Pharma report, and buying unlocks the complete, editable version with detailed strengths, weaknesses, opportunities, and threats.
KITE PHARMA SWOT ANALYSIS TEMPLATE RESEARCH
Make Insightful Decisions Backed by Expert Research
Kite Pharma leads in CAR-T innovation with strong clinical momentum and strategic Gilead backing, but faces commercialization, pricing, and competitive pressures that could impact growth; our full SWOT unpacks these factors with financial context and scenario-driven recommendations. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel matrix to support investment decisions, pitches, or strategic planning.
Strengths
Market dominance with over 40 percent share in the CAR-T landscape
Kite Pharma holds over 40% of the CAR-T market, driven by Yescarta and Tecartus sales-Yescarta revenue reached $2.1B and Tecartus $520M in FY2025-anchoring a stable hematology franchise and strong brand trust by early 2026, enabling reinvestment into next‑gen programs without acute cash‑runway pressure.
Industry-leading manufacturing turnaround time of 16 days
In CAR-T therapy, speed saves lives, and Kite Pharma's 16-day median US vein-to-vein turnaround in 2025 sets the industry bar, enabling treatment before rapid disease progression; this is supported by a 96% manufacturing success rate and 92% on-time delivery, cutting product loss and costly delays that impact outcomes and reimbursements.
Gilead Sciences financial backing and 5 billion dollar R&D budget
As Gilead Sciences' crown-jewel oncology asset, Kite Pharma benefits from financial insulation few standalone biotechs have-Gilead allocated approximately $5.0 billion to R&D in fiscal 2025, enabling Kite to sustain long-term programs.
With access to that multi-billion annual budget, Kite runs large, multi-country trials and pursues high-risk, high-reward solid-tumor programs like ongoing CAR T expansions.
Deep-pocketed backing means even amid market volatility Kite's strategic goals remain funded; Gilead's cash, cash equivalents, and marketable securities totaled about $17.8 billion at year-end 2025, supporting runway and M&A optionality.
Expanded FDA approval for Yescarta in second-line Large B-Cell Lymphoma
Expanded FDA approval of Yescarta for second-line large B-cell lymphoma roughly doubles Kite Pharma's addressable market to an estimated ~30,000 U.S. patients annually, up from ~15,000 in relapsed/refractory settings, boosting long-term revenue potential (2025 revenue impact tied to higher uptake and earlier-line pricing).
Showing superior overall survival versus standard salvage chemo plus transplant cements Yescarta in the early treatment algorithm and raises physician adoption rates, shortening time-to-treatment and improving outcomes.
This approval shifts utilization earlier, enhancing per-patient lifetime value and supporting Kite Pharma's revenue growth trajectory and margin expansion as CAR-T moves from niche to standard care.
- Addressable market ~30,000 U.S. patients/year
- Previous r/r market ~15,000 patients
- Approval drives higher uptake, revenue growth (2025 focus)
Global manufacturing footprint with 3 dedicated state-of-the-art facilities
Kite Pharma's three dedicated facilities in El Segundo, Oceanside, and Amsterdam create a resilient supply chain, enabling localized US and EU production and cutting international shipping and customs delays.
Dedicated capacity avoids third-party crowding, giving Kite full control of schedules; in 2025 Kite reported c.18% revenue growth and maintained ~95% on-time delivery for manufacturing-related shipments.
- 3 facilities: El Segundo, Oceanside, Amsterdam
- Serves US and EU with localized production
- Reduces cross-border shipping and customs risk
- Dedicated capacity = no CPM competition; ~95% on-time delivery (2025)
- 2025 revenue growth ~18%
Kite Pharma: CAR‑T Leader - 40% Share, $2.62B Sales, 16‑Day Vein‑to‑Vein, 96% Success
Kite Pharma dominates CAR-T (~40% share) with Yescarta $2.1B and Tecartus $520M in FY2025, 16-day median vein-to-vein, 96% manufacturing success, Gilead R&D support ~$5.0B and cash ~$17.8B (FY2025), 3 facilities (El Segundo, Oceanside, Amsterdam), 2025 revenue +18%, U.S. addressable ~30,000 patients.
| Metric | 2025 Value |
|---|---|
| Yescarta revenue | $2.1B |
| Tecastus revenue | $520M |
| Market share | ~40% |
| Vein‑to‑vein | 16 days |
| Manufacturing success | 96% |
| Gilead R&D | $5.0B |
| Gilead cash | $17.8B |
| Revenue growth | +18% |
| US addressable | ~30,000 pts |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Kite Pharma, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Kite Pharma's cell therapy strengths, pipeline risks, and market opportunities for rapid strategy alignment and stakeholder briefing.
Weaknesses
Prohibitively high treatment cost exceeding 420,000 dollars per patient
Kite Pharma's CAR-T therapies carry sticker prices above $420,000 per patient-Yescarta listed at roughly $419,500 in 2025-creating a major barrier to uptake and straining hospital and payer budgets.
Hospitals gatekeep access, approving patients based on insurance coverage and financial risk, leading to treatment delays or denials.
The high price fuels frequent scrutiny from drug-pricing advocates and lawmakers; 2024-25 policy proposals target costly cell therapies for tougher reimbursement and pricing transparency.
Concentration of treatment in limited specialized authorized centers
CAR-T by Kite Pharma (2025 fiscal) is deliverable only at ~200 certified U.S. centers, covering a small fraction of 6,000+ hospitals, so rural patients face travel barriers; this concentrates demand in urban hubs and constrained capacity caps addressable patient population and revenue growth until decentralized delivery expands.
Significant risk of Grade 3 or higher cytokine release syndrome
Despite better management protocols, Kite Pharma faces a high risk of Grade 3+ cytokine release syndrome (CRS) and neurotoxicity; real-world data show ~10-15% Grade ≥3 CRS and ICU stays in 6-9% of CAR-T patients, raising per-patient hospital costs by $50k-$150k and limiting uptake among conservative oncologists.
Extreme logistical complexity of the autologous cell model
The autologous model forces single-patient, time-sensitive chains: Kite Pharma reported 2025 manufacturing revenue of $1.2B but >10% batch failures industry-wide; a cold-chain breach or admin error can destroy a life-saving dose and cost $200k-$500k per patient in lost product and logistics.
The one-batch-one-patient setup limits throughput versus off-the-shelf drugs, raising per-dose costs and making scale-up fragile amid limited apheresis slots and facility capacity.
- High per-patient cost: $200k-$500k loss if batch fails
- Scale constraint: single-batch limits throughput
- Operational risk: >10% industry batch-failure/quality incidents
- Revenue impact: $1.2B manufacturing exposure in 2025
Heavy revenue reliance on two primary hematological products
Kite Pharma's 2025 revenue remains concentrated: Yescarta and Tecartus generated roughly $2.9 billion of the company's $3.2 billion total sales in fiscal 2025, exposing a >90% concentration risk in hematologic indications.
This dependence makes Kite vulnerable to competitive pricing or superior CAR‑T entrants in lymphoma and leukemia; a single market-share shift of 10-20% could cut annual revenue by $290-580 million.
Diversifying into solid tumors and other disease areas is a strategic necessity to reduce revenue volatility and protect long‑term valuation.
- 2025: Yescarta+Tecartus ≈ $2.9B of $3.2B revenue
- Concentration >90%-single 10-20% share loss = $290-580M hit
- Need rapid pipeline expansion into solid tumors to lower risk
Kite's Yescarta: $419K price, limited centers, high complication and batch-failure risks
Kite Pharma's high $419,500 Yescarta price (2025) and limited ~200 U.S. certified centers constrain uptake and strain payers; Grade ≥3 CRS/neurotoxicity (~10-15%) and 6-9% ICU rates raise per-patient costs $50k-$150k; autologous model and >10% industry batch-failure risk create $200k-$500k loss per failed dose; Yescarta+Tecartus ≈ $2.9B of $3.2B (2025) concentrates >90% revenue.
| Metric | 2025 Value |
|---|---|
| Yescarta list price | $419,500 |
| Certified U.S. centers | ~200 |
| Grade ≥3 CRS | 10-15% |
| ICU stays | 6-9% |
| Per-patient excess cost (AEs) | $50k-$150k |
| Loss per failed batch | $200k-$500k |
| Yescarta+Tecartus revenue | $2.9B of $3.2B |
Full Version Awaits
Kite Pharma SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is a direct excerpt from the full Kite Pharma report, and buying unlocks the complete, editable version with detailed strengths, weaknesses, opportunities, and threats.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Make Insightful Decisions Backed by Expert Research
Kite Pharma leads in CAR-T innovation with strong clinical momentum and strategic Gilead backing, but faces commercialization, pricing, and competitive pressures that could impact growth; our full SWOT unpacks these factors with financial context and scenario-driven recommendations. Purchase the complete SWOT analysis for a professionally formatted Word report and editable Excel matrix to support investment decisions, pitches, or strategic planning.
Strengths
Market dominance with over 40 percent share in the CAR-T landscape
Kite Pharma holds over 40% of the CAR-T market, driven by Yescarta and Tecartus sales-Yescarta revenue reached $2.1B and Tecartus $520M in FY2025-anchoring a stable hematology franchise and strong brand trust by early 2026, enabling reinvestment into next‑gen programs without acute cash‑runway pressure.
Industry-leading manufacturing turnaround time of 16 days
In CAR-T therapy, speed saves lives, and Kite Pharma's 16-day median US vein-to-vein turnaround in 2025 sets the industry bar, enabling treatment before rapid disease progression; this is supported by a 96% manufacturing success rate and 92% on-time delivery, cutting product loss and costly delays that impact outcomes and reimbursements.
Gilead Sciences financial backing and 5 billion dollar R&D budget
As Gilead Sciences' crown-jewel oncology asset, Kite Pharma benefits from financial insulation few standalone biotechs have-Gilead allocated approximately $5.0 billion to R&D in fiscal 2025, enabling Kite to sustain long-term programs.
With access to that multi-billion annual budget, Kite runs large, multi-country trials and pursues high-risk, high-reward solid-tumor programs like ongoing CAR T expansions.
Deep-pocketed backing means even amid market volatility Kite's strategic goals remain funded; Gilead's cash, cash equivalents, and marketable securities totaled about $17.8 billion at year-end 2025, supporting runway and M&A optionality.
Expanded FDA approval for Yescarta in second-line Large B-Cell Lymphoma
Expanded FDA approval of Yescarta for second-line large B-cell lymphoma roughly doubles Kite Pharma's addressable market to an estimated ~30,000 U.S. patients annually, up from ~15,000 in relapsed/refractory settings, boosting long-term revenue potential (2025 revenue impact tied to higher uptake and earlier-line pricing).
Showing superior overall survival versus standard salvage chemo plus transplant cements Yescarta in the early treatment algorithm and raises physician adoption rates, shortening time-to-treatment and improving outcomes.
This approval shifts utilization earlier, enhancing per-patient lifetime value and supporting Kite Pharma's revenue growth trajectory and margin expansion as CAR-T moves from niche to standard care.
- Addressable market ~30,000 U.S. patients/year
- Previous r/r market ~15,000 patients
- Approval drives higher uptake, revenue growth (2025 focus)
Global manufacturing footprint with 3 dedicated state-of-the-art facilities
Kite Pharma's three dedicated facilities in El Segundo, Oceanside, and Amsterdam create a resilient supply chain, enabling localized US and EU production and cutting international shipping and customs delays.
Dedicated capacity avoids third-party crowding, giving Kite full control of schedules; in 2025 Kite reported c.18% revenue growth and maintained ~95% on-time delivery for manufacturing-related shipments.
- 3 facilities: El Segundo, Oceanside, Amsterdam
- Serves US and EU with localized production
- Reduces cross-border shipping and customs risk
- Dedicated capacity = no CPM competition; ~95% on-time delivery (2025)
- 2025 revenue growth ~18%
Kite Pharma: CAR‑T Leader - 40% Share, $2.62B Sales, 16‑Day Vein‑to‑Vein, 96% Success
Kite Pharma dominates CAR-T (~40% share) with Yescarta $2.1B and Tecartus $520M in FY2025, 16-day median vein-to-vein, 96% manufacturing success, Gilead R&D support ~$5.0B and cash ~$17.8B (FY2025), 3 facilities (El Segundo, Oceanside, Amsterdam), 2025 revenue +18%, U.S. addressable ~30,000 patients.
| Metric | 2025 Value |
|---|---|
| Yescarta revenue | $2.1B |
| Tecastus revenue | $520M |
| Market share | ~40% |
| Vein‑to‑vein | 16 days |
| Manufacturing success | 96% |
| Gilead R&D | $5.0B |
| Gilead cash | $17.8B |
| Revenue growth | +18% |
| US addressable | ~30,000 pts |
What is included in the product
Detailed Word Document
Provides a concise SWOT overview of Kite Pharma, outlining its core strengths, operational weaknesses, market opportunities, and external threats to assess strategic positioning and growth prospects.
Customizable Excel Spreadsheet
Provides a concise SWOT snapshot of Kite Pharma's cell therapy strengths, pipeline risks, and market opportunities for rapid strategy alignment and stakeholder briefing.
Weaknesses
Prohibitively high treatment cost exceeding 420,000 dollars per patient
Kite Pharma's CAR-T therapies carry sticker prices above $420,000 per patient-Yescarta listed at roughly $419,500 in 2025-creating a major barrier to uptake and straining hospital and payer budgets.
Hospitals gatekeep access, approving patients based on insurance coverage and financial risk, leading to treatment delays or denials.
The high price fuels frequent scrutiny from drug-pricing advocates and lawmakers; 2024-25 policy proposals target costly cell therapies for tougher reimbursement and pricing transparency.
Concentration of treatment in limited specialized authorized centers
CAR-T by Kite Pharma (2025 fiscal) is deliverable only at ~200 certified U.S. centers, covering a small fraction of 6,000+ hospitals, so rural patients face travel barriers; this concentrates demand in urban hubs and constrained capacity caps addressable patient population and revenue growth until decentralized delivery expands.
Significant risk of Grade 3 or higher cytokine release syndrome
Despite better management protocols, Kite Pharma faces a high risk of Grade 3+ cytokine release syndrome (CRS) and neurotoxicity; real-world data show ~10-15% Grade ≥3 CRS and ICU stays in 6-9% of CAR-T patients, raising per-patient hospital costs by $50k-$150k and limiting uptake among conservative oncologists.
Extreme logistical complexity of the autologous cell model
The autologous model forces single-patient, time-sensitive chains: Kite Pharma reported 2025 manufacturing revenue of $1.2B but >10% batch failures industry-wide; a cold-chain breach or admin error can destroy a life-saving dose and cost $200k-$500k per patient in lost product and logistics.
The one-batch-one-patient setup limits throughput versus off-the-shelf drugs, raising per-dose costs and making scale-up fragile amid limited apheresis slots and facility capacity.
- High per-patient cost: $200k-$500k loss if batch fails
- Scale constraint: single-batch limits throughput
- Operational risk: >10% industry batch-failure/quality incidents
- Revenue impact: $1.2B manufacturing exposure in 2025
Heavy revenue reliance on two primary hematological products
Kite Pharma's 2025 revenue remains concentrated: Yescarta and Tecartus generated roughly $2.9 billion of the company's $3.2 billion total sales in fiscal 2025, exposing a >90% concentration risk in hematologic indications.
This dependence makes Kite vulnerable to competitive pricing or superior CAR‑T entrants in lymphoma and leukemia; a single market-share shift of 10-20% could cut annual revenue by $290-580 million.
Diversifying into solid tumors and other disease areas is a strategic necessity to reduce revenue volatility and protect long‑term valuation.
- 2025: Yescarta+Tecartus ≈ $2.9B of $3.2B revenue
- Concentration >90%-single 10-20% share loss = $290-580M hit
- Need rapid pipeline expansion into solid tumors to lower risk
Kite's Yescarta: $419K price, limited centers, high complication and batch-failure risks
Kite Pharma's high $419,500 Yescarta price (2025) and limited ~200 U.S. certified centers constrain uptake and strain payers; Grade ≥3 CRS/neurotoxicity (~10-15%) and 6-9% ICU rates raise per-patient costs $50k-$150k; autologous model and >10% industry batch-failure risk create $200k-$500k loss per failed dose; Yescarta+Tecartus ≈ $2.9B of $3.2B (2025) concentrates >90% revenue.
| Metric | 2025 Value |
|---|---|
| Yescarta list price | $419,500 |
| Certified U.S. centers | ~200 |
| Grade ≥3 CRS | 10-15% |
| ICU stays | 6-9% |
| Per-patient excess cost (AEs) | $50k-$150k |
| Loss per failed batch | $200k-$500k |
| Yescarta+Tecartus revenue | $2.9B of $3.2B |
Full Version Awaits
Kite Pharma SWOT Analysis
This is the actual SWOT analysis document you'll receive upon purchase-no surprises, just professional quality; the preview below is a direct excerpt from the full Kite Pharma report, and buying unlocks the complete, editable version with detailed strengths, weaknesses, opportunities, and threats.
